RWD Study in HER2+ mBC Patients in Third-Line Therapy
RWD Study in HER2+ mBC Patients in Third-Line Therapy
This retrospective observational study will collect Canadian real-world data (RWD) from HER2+
 metastatic breast cancer (mBC) patients to describe treatment sequences of all therapies
 received in the metastatic setting, to measure overall survival (OS), progression free
 survival (PFS), time to next active anti-cancer therapy, and to estimate the health resources
 utilization (HRU) during third-line therapy.
The proportion of treatment received during all lines of therapy in the metastatic setting
 will be described. The 2-year survival rate and median OS with interquartile range (IQR) for
 third-line therapy will be calculated. HRU data and costs during third-line therapy will be
 collected.
Inclusion Criteria:

 Male or female patients (≥18 years of age)

 Patients with stage IV breast cancer

 Patients with HER2+ status in metastatic setting

 Patients that received at least two lines of active anti-cancer drugs due to disease
 progression.

 Patients that began third-line therapy prior to October 31, 2018.

 Exclusion Criteria:

 Patients treated with an investigational anticancer agent in the ≥ 3rd line setting